Potential use of rapamycin in HIV infection
- 11 November 2010
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 70 (6), 784-793
- https://doi.org/10.1111/j.1365-2125.2010.03735.x
Abstract
The strong need for the development of alternative anti-HIV agents is primarily due to the emergence of strain-resistant viruses, the need for sustained adherence to complex treatment regimens and the toxicity of currently used antiviral drugs. This review analyzes proof of concept studies indicating that the immunomodulatory drug rapamycin (RAPA) possesses anti-HIV properties both in vitro and in vivo that qualifies it as a potential new anti-HIV drug. It represents a literature review of published studies that evaluated the in vitro and in vivo activity of RAPA in HIV. RAPA represses HIV-1 replication in vitro through different mechanisms including, but not limited, to down regulation of CCR5. In addition RAPA synergistically enhances the anti-HIV activity of entry inhibitors such as vicriviroc, aplaviroc and enfuvirtide in vitro. RAPA also inhibits HIV-1 infection in human peripheral blood leucocytes-SCID reconstituted mice. In addition, a prospective nonrandomized trial of HIV patient series receiving RAPA monotherapy after liver transplantation indicated significantly better control of HIV and hepatitis C virus (HCV) replication among patients taking RAPA monotherapy. Taken together, the evidence presented in this review suggests that RAPA may be a useful drug that should be evaluated for the prevention and treatment of HIV-1 infection.This publication has 64 references indexed in Scilit:
- Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravirJournal of Antimicrobial Chemotherapy, 2010
- Advances in the Development of Microbicides for the Prevention of HIV InfectionCurrent Infectious Disease Reports, 2010
- mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in MiceCancer Cell, 2009
- Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1Proceedings of the National Academy of Sciences of the United States of America, 2008
- Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycinClinical and Experimental Immunology, 2008
- Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140)Antimicrobial Agents and Chemotherapy, 2008
- Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic ImplicationsJournal of Virology, 2007
- Rapamycin Reduces CCR5 Density Levels on CD4 T Cells, and This Effect Results in Potentiation of Enfuvirtide (T-20) against R5 Strains of Human Immunodeficiency Virus Type 1 In VitroAntimicrobial Agents and Chemotherapy, 2007
- Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycinCancer Cell, 2006
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005